LUCEMYRA
Peaklofexidine hydrochloride
NDAORALTABLETPriority Review
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Mechanism of Action
alpha-2 adrenergic agonist that binds to receptors on adrenergic neurons. This reduces the release of norepinephrine and decreases sympathetic tone.
Clinical Trials (3)
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
Started Jun 2025
0Opioid Withdrawal (Disorder)Opioid Use Disorder
A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution
Started Feb 2021
16 enrolled
Normal Healthy Volunteers
Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal
Started Aug 2019
4 enrolled
Opioid Withdrawal (Disorder)